Alzamend Neuro™, Inc. has developed a few unique approaches for combating Alzheimer’s disease (“AD”), namely through immunotherapy and leveraging cocrystal technology for drug delivery. Current drugs approved by the FDA for AD only address symptoms and provide no benefit to the impaired immune system of patients diagnosed with Alzheimer’s disease.
The first patented solution that Alzamend™ has licensed to move to commercialization is a mutant-peptide immunotherapy that is designed to be used both as a treatment and vaccine against AD (the “Technology”). The technology, known as CAO22W, was developed by Dr. Cao and his research team located at the University of South Florida. This therapy is intended to work by stimulating the body’s own immune system to prevent the formation and breakdown of beta amyloids, which build up in the brain to form a “plaque”. The plaque subsequently blocks the neurological brain signals, ultimately leading to the symptoms and onset of Alzheimer’s disease.
Immunotherapy is the “treatment of disease by inducing, enhancing, or suppressing an immune response.” Immunotherapies that are designed to elicit or amplify an immune response are classified as activation immunotherapies, whereas immunotherapies that reduce or suppress are classified as suppression immunotherapies. We believe that strategies to strengthen the immune system in the aged, who are most susceptible to the development of Alzheimer’s disease, could greatly enhance the effectiveness of immune-based approaches against AD.
Beta amyloid protein has been directly linked to Alzheimer’s disease and the associated neurofibrillary tangles formation seen in Alzheimer’s patients. We believe that the vaccine, in addition to dealing with plaque formation, also ameliorates the impaired immune system that is thought to be the major issue in Alzheimer’s patients.